Biological
Aldafermin clinical trials
Also written NGM282.
- studies test it
- 14
- open now
- 0
- in phase 3
- 1
- first study started
- 2013
How studies write it
Studies that test it under each name
Name
Development codes
- NGM282
- 11
Studies by the year they started
14 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 3 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 10
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 1
NGM Biopharmaceuticals, Inc (13) · Michael Camilleri, MD (1)
Studies
Open first, then newest update. How each study uses aldafermin is read from its arms, and is right about nine times in ten.
Testing it · 14
- Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)CompletedPhase 2NGM Biopharmaceuticals, IncNCT02443116Written as NGM282
- Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)CompletedPhase 2NGM Biopharmaceuticals, IncNCT03912532Written as NGM282
- A Study of NGM282 in Patients With Primary Sclerosing CholangitisCompletedPhase 2NGM Biopharmaceuticals, IncNCT02704364Written as NGM282
- A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.WithdrawnPhase 2/3NGM Biopharmaceuticals, IncNCT06654726Written as aldafermin
- Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)CompletedPhase 2NGM Biopharmaceuticals, IncNCT04210245Written as aldafermin
- Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)CompletedPhase 2Michael Camilleri, MDNCT05130047Written as Aldafermin
- Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese SubjectsCompletedPhase 1NGM Biopharmaceuticals, IncNCT04828265Written as Aldafermin
- Study of Aldafermin (NGM282) in Participants With Impaired Hepatic FunctionCompletedPhase 1NGM Biopharmaceuticals, IncNCT04823702Written as Aldafermin
- Study of Aldafermin (NGM282) in Participants With Impaired Renal FunctionCompletedPhase 1NGM Biopharmaceuticals, IncNCT04179630Written as Aldafermin (NGM282)
- Study of NGM282 in Subjects With Functional Constipation and Healthy IndividualsCompletedPhase 1/2NGM Biopharmaceuticals, IncNCT02649062Written as NGM282
- Phase 2 Study of NGM282 in Patients With Primary Biliary CirrhosisCompletedPhase 2NGM Biopharmaceuticals, IncNCT02026401Written as NGM282
- Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary CirrhosisCompletedPhase 2NGM Biopharmaceuticals, IncNCT02135536Written as NGM282
- Phase 2 Study of NGM282 in Patients With Type 2 DiabetesCompletedPhase 2NGM Biopharmaceuticals, IncNCT01943045Written as NGM282
- Phase 1 SAD and MAD Study of NGM282 in Healthy Adult ParticipantsCompletedPhase 1NGM Biopharmaceuticals, IncNCT01776528Written as NGM282
Codes
What other systems call aldafermin · ClinicalTrials.gg INT001421
- MeSH (NLM) C000710649aldaferminConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) IK9NYN31ZMALDAFERMINConfirmed FDA, NLM
- NCI Thesaurus C169769AldaferminOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710649 | aldafermin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | IK9NYN31ZM | ALDAFERMIN | Confirmed FDA, NLM |
| NCI Thesaurus | C169769 | Aldafermin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.